Tuberculosis therapy: Past, present and future

European Respiratory Journal, Supplement

Volumn 20, Issue 36, 2002, Pages

  Iseman, M D ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

Acquired immune; Deficiency syndrome; Directly observed therapy; Drug resistance treatment; Immunomodulation; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; CIPROFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; ISONIAZID; LEVOFLOXACIN; METRONIDAZOLE; MORINAMIDE; MOXIFLOXACIN; OFLOXACIN; OXAZOLIDINONE DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; TROVAFLOXACIN; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RESPONSE; LUNG TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULOSIS CONTROL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; REVIEW; TIME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; TIME FACTORS; TUBERCULOSIS;

EID: 0036064607     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (100)

1. Treatment of pulmonary tuberculosis with streptomycin and para-aminosalicylic acid
2. Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis
3. Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service Tuberculosis Therapy Trials
4. Second East African/British Medical Research Council Study. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second Report
5. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: The results up to 24 months
6. Controlled trial of 4 three-times weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: The results up to 24 months
7. Longterm follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis
8. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications
9. Directly observed therapy for tuberculosis: History of an idea
10. Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide: Results at 30 months
11. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen
12. WHO Tuberculosis Programme: Framework for effective tuberculosis control
13. Global surveillance for antituberculosis-drug resistance, 1994-1997
14. Global trends in resistance to antituberculosis drugs
15. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis
16. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: No activity of isoniazid in the continuation phase
17. The early bactericidal activity of drugs in patients with pulmonary tuberculosis
18. U.S. Public Health Service cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis
19. Controlled trial of intermittent regimens of rifampicin plus isoniazid for pulmonary tuberculosis in Singagore. The results up to 30 months
20. The clinical pharmacokinetics of rifabutin
21. Rifabutin for the treatment of newlydiagnosed pulmonary tuberculosis: A multinational, randomized, comparative study versus rifampicin
22. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis
23. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease
24. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong
25. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis
26. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report
27. TBTC Study 22 (Rifapentine Trial): Preliminary results in HIV negative patients
28. TBTC Study 22: Risk factors for relapse with once-weekly isoniazid/rifapentine (HP) in HIV-negative TB patients
29. Bacteriostatic and bactericidal activities of Benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages
30. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice
31. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model
32. Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice
33. Evaluation of rifalazil in long-term treatment regimens for tuberculosis in mice
34. Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model
35. In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280)
36. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex
37. Antituberculosis activity of ofloxacin (DL8280) on experimental tuberculosis in mice
38. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
39. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
40. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis
41. Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: Effects of a C-8 methoxyl group on survival in liquid media and in human macrophage
42. Comparative antimicrobial activities of the newly synthesized quinolone BAY 12-8039 and gatifloxacin
43. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis
44. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis
45. Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis
46. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin
47. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens
48. The treatment of multidrug-resistant tuberculosis in Turkey
49. Fluoroquinolone toxicity profiles: A review focusing on newer agents
50. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections
51. Oxazolidinones: A review
52. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model
53. Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity
54. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
55. In vitro and in vivo activities of nitroimidazole CGI 173421 against Mycobacterium tuberculosis
56. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase
57. Antituberculosis drugs and new drug development
58. Antimyco-bacterial action or thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis
59. Thiolactomycin and related analogues as novel antimycobcterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis
60. In vitro antimycobacterial activity of 5-chloropyrazinamide
61. pncA mutation as a major mechanism of pyrazinamide resistance in M. tuberculosis
62. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection
63. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya
64. The impact of human immunodeficiency virus on mortality in patients treated for tuberculosis: Two-year follow-up of cohort in Lusaka, Zambia
65. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection
66. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
67. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy
68. Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: Part I
69. Acquired rifamycin mono-resistance among patients with HIV-related tuberculosis treated with supervised once weekly rifapentine and isoniazid
70. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
71. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy
72. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
73. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy
74. Paradoxical worsening of tuberculosis in HIV-infected persons
75. Observations on the protective effect of BCG vaccination in a South Indian rural population: Fourth report
76. Variation in protection by BCG: Implications of and for heterologous immunity
77. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi
78. Randomised controlled trial of single BCG, repeated BCG, or combined BCG, and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi
79. Current tuberculosis vaccine development
80. Bacille Calmette-Guérin vaccines: A rough guide
81. Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus-positive subjects in the United States after a five-dose schedule of Mycobacterium vaccae vaccine
82. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: A randomised controlled trial
83. Use of adjunctive treatment with interferon-g in an immunocompromised patient who had refractory multidrug-resistant tuberculosis of the brain
84. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol
85. Effects of aerosolized interferon-α in patients with pulmonary tuberculosis
86. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of Imiquimod, an Immunomodulator
87. Clarithromycin significantly improves interleukin-12-mediated anti-Mycobacterium avium activity and abolishes toxicity in mice
88. Granulocyte and granulocyte-macrophage colony-stimulating factors
89. Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF
90. Immunomodulatory treatment of Mycobacterium avium complex bacteremia in patients with AIDS by use of recombinant granulocyte-macrophage colonystimulating factor
91. Levamisole as an adjunct in the treatment of pulmonary tuberculosis
92. Controlled clinical trial of levamisole in short-course chemotherapy for pulmonary tuberculosis
93. Transfer factor therapy in a patient with progressive primary tuberculosis
94. Clinical and immunologic response to antigen-specific transfer factor drug-resistant infection with Mycobacterium xenopi
95. Immunotherapy with dialyzable leukocyte extracts and studies of their antigen-specific (transfer factor) activity
96. Transfer factor treatment in a patient with progressive tuberculosis
97. Transfer factor applied to intensify the cell-mediated immunological reactions against Mycobacterium avium
98. Working Alliance for TB Drug Development, Cape Town, South Africa, February 8th, 2000